Robot-assisted surgery for early-stage kidney tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of robot-assisted laparoscopic partial nephrectomy with renal artery off-clamp for treating cT1 renal tumors. It aims to compare outcomes between traditional artery clamping and zero-clamping techniques during surgery. The study includes patients aged 18 to 90 who have confirmed T1 renal tumors and are deemed suitable for partial nephrectomy. The goal is to preserve kidney function while minimizing surgical risks and recovery time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Imaging examination confirms a T1 renal tumor (including T1a and T1b), and the investigator deems partial nephrectomy to be beneficial.
* Age ranges from 18 to 90 years.
* No history of severe kidney disease or autoimmune disorders.
* Cardiopulmonary function indicates the ability to tolerate major abdominal surgery.
* ECOG performance status score is 0 or 1.
* Willingness to undergo zero-ischemia partial nephrectomy and able to provide written informed consent, understanding and agreeing to comply with the study requirements and evaluation schedule.

Exclusion Criteria:

* Imaging assessment shows a tumor stage of ≥T2.
* Imaging indicates that the tumor is located in the renal pelvis or is a Wilms' tumor, etc.
* The investigator considers the patient unsuitable for partial nephrectomy.
* Major surgery or significant trauma occurred within 28 days prior to enrollment.
* Live vaccine received within 28 days prior to enrollment.
* Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment occurred within 14 days prior to enrollment.
* Any traditional Chinese medicine or herbal supplements for cancer treatment taken within 14 days prior to enrollment.
* Participation in any other clinical trials.

Where it's running

• The first affiliated hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Xiao Yang, PhD
• Email: yangxiao2915@163.com
• Phone: +8613951813528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cortical-plus-medullary versus medullary-only suturing for robot-assisted partial nephrectomy

  This trial tests whether using only medullary stitches instead of both medullary and cortical stitches during robot-assisted partial nephrectomy helps protect kidney function and reduce operative time and blood loss for people with localized renal cell carcinoma.

  Recruiting at 2 sites Brazilian Institute of Robotic Surgery · Salvador, Estado de Bahia and 1 other locations · NCT07190638

• Testing LXP1788 Injection for Advanced Solid Tumors

  This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 LaunXP Biomedical Co., Ltd. · Taichung and 1 other locations · NCT06883539

• Evaluating a new PET imaging method for renal cell carcinoma

  This study is testing a new type of PET scan to see if it can better diagnose and stage kidney cancer in patients who are suspected of having the disease.

  Recruiting Xijing Hospital · Xi'an, China, Shaanxi · NCT06769893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.